Biosensors International   Report issue

For profit Phase 3
Founded: Singapore Singapore (1989)
Status: No NME R&D (1989)

Organization Overview

First Clinical Trial
2013
NCT01813435
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Biosensors International

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Artery Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3